Contact this trialFirst, we need to learn more about you.
GLP-1 Receptor Agonist
Retatrutide for Chronic Kidney Disease and Obesity
Recruiting0 awardsPhase 2
Burlington, Ontario
This trial will investigate how retatrutide affects kidney health in people with obesity/overweight, CKD, and/or T2D over 31 weeks.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.